Lyell Immunopharma (LYEL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$27,000.00

Revenue (quarter)

$4,000.00

Revenue growth (year over year)

−50.00%

Gross profit (trailing twelve months)

$27,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$248.5M

Net income (quarter)

−$44.8M

Net income growth (year over year)

−4.85%

Net margin

−920285.19%

Return on equity

−93.28%

EPS (trailing twelve months)

−$12.69

Book value per share

$9.99

P/E (trailing twelve months)

—

Price to book

0.79

Debt to assets

24.86%

Payout ratio

—

Dividend yield

—

Company profile

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

• Is Lyell Immunopharma (LYEL) profitable?

  No. Lyell Immunopharma reported a net loss of $248.5M over the trailing twelve months.

• How much revenue does Lyell Immunopharma (LYEL) make?

  Lyell Immunopharma generated $27,000.00 in revenue over the trailing twelve months, down 50.00% year over year.

• How do I buy stock in Lyell Immunopharma (LYEL)?

  LYEL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.